This company listing is no longer active
Shedir Pharma Group Balance Sheet Health
Financial Health criteria checks 6/6
Shedir Pharma Group has a total shareholder equity of €37.7M and total debt of €2.8M, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are €57.4M and €19.7M respectively. Shedir Pharma Group's EBIT is €8.7M making its interest coverage ratio 57.1. It has cash and short-term investments of €8.7M.
Key information
7.3%
Debt to equity ratio
€2.77m
Debt
| Interest coverage ratio | 57.1x |
| Cash | €8.71m |
| Equity | €37.72m |
| Total liabilities | €19.69m |
| Total assets | €57.41m |
Recent financial health updates
Recent updates
Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Nov 08
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?
Apr 06What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 30
Financial Position Analysis
Short Term Liabilities: SHE's short term assets (€43.4M) exceed its short term liabilities (€15.2M).
Long Term Liabilities: SHE's short term assets (€43.4M) exceed its long term liabilities (€4.5M).
Debt to Equity History and Analysis
Debt Level: SHE has more cash than its total debt.
Reducing Debt: SHE's debt to equity ratio has reduced from 86.5% to 7.3% over the past 5 years.
Debt Coverage: SHE's debt is well covered by operating cash flow (338.7%).
Interest Coverage: SHE's interest payments on its debt are well covered by EBIT (57.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/24 21:36 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shedir Pharma Group S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gian Gadini | Banca Akros S.p.A. (ESN) |
| Maria Di Grado | KT & Partners Srl |